Janjigian YY and Braghiroli MI |
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. |
2017 |
Surg. Oncol. Clin. N. Am. |
pmid:28279471
|
Cox K et al. |
Emerging Therapeutic Strategies in Breast Cancer. |
2017 |
South. Med. J. |
pmid:28973703
|
Bhardwaj AS et al. |
A case of vasculitis in a breast cancer patient treated with T-DM1. |
2014 |
Semin. Oncol. |
pmid:25440614
|
Müller P et al. |
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. |
2015 |
Sci Transl Med |
pmid:26606967
|
Shen K et al. |
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. |
2016 |
Sci Rep |
pmid:26979925
|
Pan W et al. |
Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. |
2013 |
Sci China Life Sci |
pmid:23832249
|
Ito Y |
[Progress of molecularly targeted therapy for breast cancer]. |
2012 |
Rinsho Ketsueki |
pmid:22687976
|
Lin CM et al. |
Binding of maytansine to tubulin: competition with other mitotic inhibitors. |
1981 |
Res. Commun. Chem. Pathol. Pharmacol. |
pmid:7255878
|
Lanshoeft C et al. |
Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. |
2016 |
Rapid Commun. Mass Spectrom. |
pmid:26969923
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|